据港交所8月29日披露，可孚医疗科技股份有限公司(301087.SZ)向港交所主板递交上市申请，华泰国际、BNP PARIBAS为联席保荐人。 | [編纂]項卜的[編纂]數目 | .. | 「編纂】股H股(視乎[編纂]行使與否而定) | | --- | --- | --- | | [編纂]數目 | . . | [編纂]股H股(可予車新分配) | | [編纂]數目 | . . | 「編纂]股H股(可予重新分配及視乎「編 | | 纂]行使與否而定) | | | | 最高[編纂] : | | 每股H股[編纂]港元,另加1.0%經紀 | | 佣金、0.0027%證監會交易徵費、 | | | | 0.00015%會財局交易徵費及 | | | | 0.00565%香港聯交所交易費(須於申 | | | | 請時以港元繳足,多繳股款可予退還) | | | | 面值 每股H股人民幣1.00元 | . . | | | [編纂] : [編纂] | | | | 聯席保薦人、[編纂]·[編纂]· | | | | [編纂]及[編纂] | | | | 人 华泰国际 DND DADIDAC | | | 招股书显示，自2007年成立以来，可孚 ...

Core Viewpoint - Cofo Medical has established itself as a leading player in the home medical device industry in China, focusing on providing advanced and convenient solutions for consumers and patients since its inception in 2007 [2]. Company Overview - Cofo Medical is one of the largest home medical device companies in China, ranking second in sales among all home medical device enterprises in the country as of 2024, according to Frost & Sullivan [2]. - The company has expanded its global presence, covering over 60 countries and regions across Asia, Africa, Europe, and America, attracting a growing loyal user base [2]. Sales and Market Performance - As of 2024, Cofo Medical achieved online sales of approximately RMB 1.981 billion, ranking second among Chinese home medical device companies [2]. - In the first half of 2025, Cofo Medical's brand products performed exceptionally well across various platforms, with 12 product categories ranking first on Douyin, and multiple categories ranking in the top three on Tmall and JD [2]. Retail Presence - By June 30, 2025, Cofo Medical operated 738 self-owned stores in China, with 689 being "Jianer Hearing" service centers, covering over 135 cities [3]. - The "Jianer Hearing" service centers provide professional hearing testing services and supply various high-quality hearing aid products, ranking among the top three in the industry by the number of fitting centers in China as of the end of 2024 [3]. Financial Performance - Cofo Medical's revenue for the fiscal years 2022, 2023, 2024, and the first half of 2025 was approximately RMB 2.977 billion, RMB 2.854 billion, RMB 2.983 billion, and RMB 1.496 billion, respectively [3][5]. - The net profit for the same periods was approximately RMB 302 million, RMB 253 million, RMB 312 million, and RMB 167 million, respectively [3][5].

智通财经APP获悉，据港交所8月29日披露，可孚医疗科技股份有限公司(301087.SZ)向港交所主板递交上市申请，华泰 国际、BNP PARIBAS为联席保荐人。 招股书显示，自2007年成立以来，可孚医疗一直深耕家用医疗器械行业，始终致力于为追求优质及先进家用医疗器械的 消费者及患者提供便捷解决方案。 可孚医疗是中国最大的家用医疗器械企业之一。根据弗若斯特沙利文的资料，按2024 年的中国销售额计，公司在所有 家用医疗器械企业中排名第二。于往绩记录期间，可孚医疗积极拓展海外市场，吸引了全球日益增长的忠实用户群体。 目前，可孚医疗的全球业务版图已覆盖亚洲、非洲、欧洲及美洲的60多个国家及地区。 截至最后实际可行日期，可孚医疗已实现对天猫、京东、抖音、小红书、拼多多及药师帮等所有主流电商平台的全覆 盖。于2024年，可孚医疗的线上销售额达人民币19.81亿元，在中国家用医疗器械企业中位列第二。就2025年上半年的 销量而言，可孚医疗的品牌产品在各平台表现亮眼：在抖音家用医疗器械类目下，12个产品品类销量位列第一，24个产 品品类销量位列前三；在天猫家用医疗器械类目下，22个产品品类销量位列前三，53个产品品类 ...